All In Biotech

Drug Trial Radar · NCT02373072

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Mar 2015

Primary completion

Feb 2016

Study completion Mar 2016

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.

Conditions

  • Idiopathic Parkinson Disease

Interventions

  • PF-06649751Drug

    Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.

  • Trimethobenzamide HydrochlorideDrug

    300mg TID, Capsules. Optional in both Cohorts.

  • PlaceboDrug

    Subjects completing all three treatment periods will be receiving placebo once.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and proportion of subjects with Adverse Events (AEs)Time frame: Day 1 through 61
  2. Number of participants with vital signs data that meet criteria of potential clinical concernTime frame: Day 1 through 61
  3. Number of participants with ECG data that meet criteria of potential clinical concernTime frame: Day 1 through 61
  4. Number of participants with abnormal clinically significant laboratory measurementsTime frame: Day 1 through 61
  5. C-SSRS (suicidality assessment)Time frame: Day 1 through 61

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, LLC.

    Long Beach, California

  • MD Clinical

    Hallandale, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • SNBL Clinical Pharmacology Center, Inc.

    Baltimore, Maryland

  • Parkinson's Movement Disorder Center of Maryland

    Elkridge, Maryland

  • Neurology Consultants of Dallas, PA

    Dallas, Texas

  • Walnut Hill Medical Center

    Dallas, Texas

  • Pfizer Clinical Research Unit

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.